Acorda acquires medications
Qutenza is approved by the U.S. Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia. The company also acquired NP-1998, a Phase 3 ready, prescription strength capsaicin topical solution, which is being assessed for the treatment of neuropathic pain.
"The acquisition of Qutenza and NP-1998 enables us to expand into the area of neuropathic pain management,” said Ron Cohen, M.D., Acorda's president and CEO.
Acorda also will make up to $5 million in payments contingent upon the achievement of certain regulatory and sales milestones related to NP-1998.